Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

The recommendation comes just weeks after the US Food and Drug Administration (FDA) approved the drug for use. Lenacapavir trials were conducted in Uganda and South Africa and demonstrated 100% ...

The WHO has approved the use of a new drug to prevent HIV. The drug is called Lenacapavir, and what makes it unique is that ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...